Gregory T Tietjen

Title: Gregory T Tietjen: Innovator in Enhanced Targeting Platforms

Introduction

Gregory T Tietjen is a notable inventor based in New Haven, CT (US). He has made significant contributions to the field of biotechnology, particularly in the development of enhanced targeting platforms. His innovative work focuses on improving the delivery of therapeutic agents to specific cells, tissues, and organs.

Latest Patents

Gregory T Tietjen holds a patent for an "Enhanced Targeting Platform." This platform technology provides particle and nucleic acid conjugates, along with compositions that enhance targeting to cells, tissues, and organs. The technology involves synthetic binding proteins, such as polypeptide monobodies, which are covalently conjugated to the surface of particles or nucleic acids. This allows for the linking of targeting agents to the surfaces of these deliverables. The particles can also include therapeutic, diagnostic, or prophylactic agents, making them versatile for various applications, including ex vivo perfusion of mammalian organs and in vivo disease treatment. He has 1 patent to his name.

Career Highlights

Throughout his career, Gregory T Tietjen has worked with prestigious institutions, including Yale University and New York University. His research has focused on advancing the capabilities of targeted delivery systems in medical applications. His work has the potential to revolutionize how treatments are administered, making them more effective and precise.

Collaborations

Gregory T Tietjen has collaborated with esteemed colleagues, including W Mark Saltzman and Shohei Koide. These collaborations have further enriched his research and contributed to the development of innovative solutions in the field of biotechnology.

Conclusion

Gregory T Tietjen is a pioneering inventor whose work in enhanced targeting platforms is shaping the future of medical treatments. His contributions to biotechnology demonstrate the importance of innovation in improving healthcare outcomes.